You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Financement des régimes fondés sur les données probantes

Les monographies et fiches d’information sur les médicaments et les régimes à l’intention des patients offrent des renseignements sur la posologie et l’administration des traitements contre le cancer.

Elles ne sont fournies qu’à titre indicatif et ne visent pas à remplacer les renseignements posologiques ni les recommandations d’un médecin.

Si vous avez des questions à propos du financement des TS-PBQ, veuillez consulter la Foire aux questions (anglais) de notre site Web.

Découvrez les fiches d’information améliorées sur les régimes à l’intention des patients, élaborées en collaboration avec les conseillers des patients et des familles. Disponible en français.

Regimens

11 Items
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
May 2019
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
New Drug Funding Program
    Denosumab - Hormone Refractory Prostate Cancer
Exceptional Access Program
    denosumab - Bony metastases in hormone refractory prostate cancer, with specific criteria
Jul 2018
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    iMAtinib - Adults with newly diagnosed Ph+ ALL, with specific criteria
May 2019
Cancer Type: Gastrointestinal, Gastrointestinal Stromal Tumours, Sarcoma, GIST     
Intent: Adjuvant
Funding:
Exceptional Access Program
    iMAtinib - Adjuvant Gastrointestinal Stromal Tumours, with specific criteria
Jun 2019
Cancer Type: Gastrointestinal, Gastrointestinal Stromal Tumours, Sarcoma, GIST     
Intent: Palliative
Funding:
Exceptional Access Program
    iMAtinib - Metastatic Gastrointestinal Stromal Tumours, with specific criteria
Aug 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    iMAtinib - Adults with newly diagnosed Ph+ ALL, with specific criteria
Jun 2019
Cancer Type: Gastrointestinal, Gastrointestinal Stromal Tumours, Sarcoma, GIST     
Intent: Palliative
Funding:
Exceptional Access Program
    regorafenib - For the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST), according to specific criteria.
Jun 2019
Cancer Type: Gastrointestinal, Hepatobiliary / Liver / Bile Duct     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of hepatocellular carcinoma according to clinical criteria
Sep 2019
Cancer Type: Gastrointestinal, Gastrointestinal Stromal Tumours, Sarcoma, GIST     
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
Jun 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Metastatic renal cell carcinoma, with specific criteria
Aug 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumours (pNET), according to specific criteria
Jun 2019